Alvaro Tomás, de la Cruz-Merino Luis, Henao-Carrasco Fernando, Villar Rodríguez José Luis, Vicente Baz David, Codes Manuel de Villena Manuel, Provencio Mariano
Pathology Department, Hospital de Tortosa Verge de la Cinta, 41300 Tortosa, Spain.
J Biomed Biotechnol. 2010;2010. doi: 10.1155/2010/846872. Epub 2010 Aug 12.
Lymphomas represent a wide group of heterogenic diseases with different biological and clinical behavior. The underlying microenvironment-specific composition seems to play an essential role in this scenario, harboring the ability to develop successful immune responses or, on the contrary, leading to immune evasion and even promotion of tumor growth. Depending on surrounding lymphoid infiltrates, lymphomas may have different prognosis. Moreover, recent evidences have emerged that confer a significant impact of main lymphoma's treatment over microenvironment, with clinical consequences. In this review, we summarize these concepts from a pathological and clinical perspective. Also, the state of the art of lymphoma's anti-idiotype vaccine development is revised, highlighting the situations where this strategy has proven to be successful and eventual clues to obtain better results in the future.
淋巴瘤是一大类具有不同生物学和临床行为的异质性疾病。潜在的微环境特异性组成似乎在这种情况下起着至关重要的作用，它具有引发成功免疫反应的能力，或者相反，导致免疫逃逸甚至促进肿瘤生长。根据周围的淋巴细胞浸润情况，淋巴瘤可能有不同的预后。此外，最近有证据表明，主要淋巴瘤治疗对微环境有重大影响，并产生临床后果。在本综述中，我们从病理学和临床角度总结了这些概念。此外，还对淋巴瘤抗独特型疫苗的发展现状进行了综述，强调了该策略已被证明成功的情况以及未来取得更好结果的潜在线索。
